The quality of antibodies – measured by their specificity, sensitivity and repeatability – is a priority for our customers and, therefore, a major focus of our work and investment at Abcam. We are investing to increase the standards and breadth of product validation, including over 1,400 products that now benefit from our market-leading knockout validation. Our investments in the latest recombinant antibody production technology mean that our more than 12,800 recombinant antibodies ensure the highest standard of repeatability for researchers and drug development teams. At the same time, we continue to work closely with our supplier partners to ensure that they meet our high standards.
Together, these initiatives are ensuring we continuously improve the reliability and performance of our products, helping to earn the loyalty of our existing customers whilst attracting new ones.
Professor Jinzhong Qin specialises in regulatory mechanisms of epigenetics, particularly in the proliferation and differentiation of stem cells. He has come to rely upon the merits of Abcam’s range of highly sensitive and specific recombinant RabMAb® products. As a result, he recently partnered with Abcam to develop custom RabMAb® products. This has led to several new primary antibodies being added to the Abcam catalogue against important targets (like polycomb proteins and M-phase phosphoproteins). These have been pivotal in Professor Qin’s research discoveries.
Professor Jinzhong Qin
Nanjing University, Nanjing, China